Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive.
Under the order, first announced in February 2016, the companies are required to
divest two dosage strengths of generic doxycycline monohydrate capsules, which are used to treat bacterial infections, and generic mesalamine extended release capsules, which are used to treat ulcerative colitis.
The Commission vote approving the final order was 3-0. (FTC File No. 151 0202; the staff contact is Kari A. Wallace, Bureau of Competition, 202-326-3085)
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.